The American public is completely misunderstanding the crisis unfolding in our Medicare Advantage system. The Centers for Medicare and Medicaid Services recently declined to award Elevance Health a $115 million quality bonus, citing the insurer’s drop in annual star ratings. The media has lazily framed this as a mega-corporation failing to provide adequate care to vulnerable seniors. But what the studies won't tell you is that expecting a health insurance company to actually facilitate healthcare is not just scientifically unsound, it is bordering on clinical abuse.
The CMS star rating system is ostensibly designed to measure how well Medicare Advantage plans manage chronic conditions, facilitate preventative screenings, and handle customer service. It is a five-star scale, much like the one you might use to evaluate a moderately priced hotel or a vacuum cleaner. Elevance, like any of us, experienced a slight dip in performance, missing the critical four-star threshold that triggers massive federal bonus payments. For this completely natural fluctuation, the government has decided to confiscate nine figures of hard-earned taxpayer subsidies.
I recently sat on a panel at the Aspen Ideas Health festival alongside several managed-care executives, and the exhaustion in their eyes was palpable. They are being asked to do the impossible: ensure that millions of elderly Americans somehow experience positive health outcomes while simultaneously aggressively restricting access to the very network providers who might deliver them. It is a cognitive dissonance that would break a lesser industry, yet we expect them to do it with a smile and a perfect patient-satisfaction score.
As a clinician, I frequently have to remind my own patients that their personal health journeys are intrinsically tied to the quarterly earnings reports of the companies managing their risk pools. When a patient refuses to improve their blood pressure, they are not just harming their own cardiovascular system. They are actively sabotaging a corporate entity’s ability to achieve a four-star Healthcare Effectiveness Data and Information Set metric. It is deeply selfish behavior, and frankly, I am tired of pretending otherwise.
To understand the fundamental injustice of the current framework, one must examine the specific metrics CMS uses to determine these ratings. The government heavily weights factors like medication adherence and hospital readmission rates. But any honest observer knows that an insurer has absolutely no control over whether an eighty-year-old remembers to take their prescribed statin. Penalizing Elevance for the cognitive decline of its customer base is like fining a casino because the gamblers are bad at math. It ignores the fundamental nature of the transaction.
Elevance is absolutely right to sue the federal government over this $115 million discrepancy. The lawsuit argues that CMS did not calculate the star ratings appropriately, and anyone who has ever tried to calculate the return on investment of a denied MRI knows exactly how subjective these algorithms can be. We are treating patient mortality and hospital readmission rates as objective facts, rather than recognizing them for what they truly are: heavily biased data points collected by people who are already sick.
Consider the customer service component of the star ratings, which heavily penalizes insurers for long wait times, dropped calls, and denied appeals. This represents a fundamental misunderstanding of the healing process.
Navigating a labyrinthine automated phone system to argue with a claims adjuster about whether a prescribed generic beta-blocker is medically necessary builds cognitive resilience. It keeps the mind sharp. By artificially smoothing this friction to chase a five-star rating, CMS is actively depriving seniors of the neurological stimulation required to stave off dementia.
The federal government is operating under the archaic assumption that a health insurer's primary function is to disburse funds for medical treatment.
Lin’s point is unassailable. The $115 million that CMS is withholding was never intended to be spent on actual medical care. That money is the essential lifeblood of innovation. It is earmarked for vital corporate functions: developing slicker direct-mail brochures featuring vibrant, silver-haired actors playing pickleball, and funding the sophisticated artificial intelligence models required to deny claims in milliseconds rather than days.
Without those bonuses, the Medicare Advantage market faces a terrifying chilling effect. If we establish a precedent where insurers are only paid extra when they objectively improve the health of the enrolled population, the entire business model collapses overnight.
I have reviewed the data, and it is clear that tying revenue to outcomes creates a perverse incentive for insurers to actually cover treatments. This inevitably leads to a dangerous over-utilization of the healthcare system. If people know their insurance will pay for their colonoscopy, they will simply go out and get colonoscopies, entirely unchecked, draining resources from the administrative infrastructure that makes American medicine the envy of the world.
Furthermore, we must address the psychological toll this punitive rating system takes on the C-suite. A multi-billion-dollar enterprise does not simply bounce back from being told it is merely a three-and-a-half-star operation.
We must also recognize the sheer bravery of Elevance’s legal strategy. By reclassifying a sprawling federal lawsuit as a necessary operational expense, they are pioneering a holistic approach to corporate survival. The millions of dollars currently being diverted to antitrust attorneys and regulatory litigators is, in a very real sense, a form of preventative medicine. It prevents the company from suffering the acute trauma of missing its quarterly revenue guidance.
When I am consulting with major payers, I always emphasize that true wellness begins with robust cash reserves. You cannot pour from an empty cup, and you certainly cannot optimize shareholder value from an escrow account tied up in federal litigation. Suing the government for $115 million is not an act of corporate greed; it is a profound expression of self-care. Elevance is setting boundaries. Elevance is refusing to internalize the toxic feedback of federal regulators.
The only logical path forward is a radical deregulation of the star rating system. Insurers must be allowed to grade their own homework.
Until CMS recognizes that the highest form of healthcare is a fully actualized corporate balance sheet, we will continue to see these tragic, preventable lawsuits. We must immediately release the $115 million to Elevance, apologize for questioning their algorithms, and formally recognize that the greatest threat to a five-star rating has always been the patients themselves.